| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | 0.051 | 0.4 |
| mRNA | HC-067047 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.047 | 0.4 |
| mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | -0.065 | 0.4 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | 0.046 | 0.4 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.032 | 0.4 |